Find your next paid study

Convergent TherapeuticsNCT06549465

~$75 – $2,800

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer (CRPC)Metastatic Castration-resistant Prostate Carcinoma

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DES…

TechnoGenesys, Inc.NCT06705686

Actual pay is set by the research site.

Phase 2

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an in…

Castration-Resistant Prostate Cancer (CRPC)Castration-Resistant Prostate CancerProstate Cancer+1 more

Monte Rosa Therapeutics, IncNCT07745361

~$75 – $2,800

Actual pay is set by the research site.

Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2…

Deciphera Pharmaceuticals, LLCNCT06966024

Actual pay is set by the research site.

Metastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination With Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with …

Regeneron PharmaceuticalsNCT07594106

Actual pay is set by the research site.

Prostate CancerRenal CancerUrethral Cancer+3 more

A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies

This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to f…

Rahul AggarwalNCT05888532

Actual pay is set by the research site.

ER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study …

IDEAYA BiosciencesNCT07540572

Actual pay is set by the research site.

Phase 2

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate or Darolutamide

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with met…

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Prostate Cancer Clinical Trials ConsortiumNCT06844383

~$75 – $2,000

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer

A Phase Ib Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that…

University of UtahNCT05613894

~$150 – $3,000

Actual pay is set by the research site.

Advanced or Metastatic Adrenocortical CarcinomaMetastatic Castration-resistant Prostate Cancer

A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Daiichi SankyoNCT07189403

~$150 – $4,500

Actual pay is set by the research site.

Phase 2

MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer

This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARP…

Recurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate CancerCastration-resistant Prostate Cancer+1 more

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT06378866

Metastatic Castration-resistant Prostate Cancer

A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Ca…